anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The purpose of this study was to assess the combined effects of type 2 diabetes (T2D) and hearing loss on the level of distress in individuals with diabetes.
METHODS: The 2021 National Health Interview Survey included 2633 adults (ages 18+) with T2D who reported perceived hearing loss, level of diabetes-related distress, household composition, and demographic characteristics. Logistic regressions evaluated these association between hearing loss and diabetes distress controlling for age, income, region of residence, marital status, rurality, educational attainment, insurance coverage, time since diabetes diagnosis, and household composition. Interaction effects examined differential associations between demographic groups.
RESULTS: About 3.5% of adults with T2D in the sample reported hearing loss, and 70% reported diabetes-related distress. Results indicated that diabetes distress was significantly more likely among individuals with hearing loss (OR = 2.08) relative to their hearing counterparts. Additionally, females (OR = 1.50), low-income earners (OR = 1.84), middle-income earners (OR = 1.41), non-Hispanic Blacks (OR = 1.58), and Hispanics (OR = 1.75) with diabetes had higher odds of reporting diabetes distress. Interaction analyses indicated that non-Hispanic Blacks and Hispanics with hearing loss had a 37% and 19%, respectively, higher likelihood of diabetes distress relative to non-Hispanic Whites with hearing loss.
CONCLUSION: Diabetes distress was more likely among individuals with hearing loss. These findings suggest the communication challenges of individuals with hearing loss may explain the observed differences in distress.
Lichen striatus (LS), linear psoriasis (LPs), linear cutaneous lupus erythematosus (LCLE) and linear lichen planus (LLP) often have similar clinical manifestations, which makes clinical diagnosis with the naked eye difficult; therefore, they are easily misdiagnosed. The purpose of this study was to determine whether reflectance confocal microscopy (RCM) is helpful in differentiating between these four linear dermatoses in children. This retrospective study included 14 patients with LS, nine with LPs, eight with LCLE and 12 with LLP. All patients were analysed using RCM, and biopsies were collected from lesions previously imaged by RCM. For LS, the dermal papillary rings were partially absent, but when present, manifested with small, homogeneously round, bright cells and occasionally highly refractive plump cellular structures, aggregated in clusters. LPs exhibited dark cyst-like structures with small, bright, round cells aggregated at the epidermal level; at the dermal-epidermal junction, homogeneously distributed, enlarged, faint dermal papillary rings and numerous enlarged low-refractive canalicular structures were observed in the superficial dermis. LCLE and LLP exhibited similar manifestations, including epidermal disarray, almost total absence of dermal papillary rings, and various sized refractive structures densely distributed in the dermis. The key distinguishing features of LCLE were the different sized structures mainly clustered around hair follicles, while LLP demonstrated dense structures with a scattered distribution. RCM may be used to distinguish between the key features of LS, LPs, LCLE and LLP in children.
FIELD: medicine.SUBSTANCE: invention discloses a method for fasting course for severely ill patients. Described is a method for starvation, in which food and fluids are excluded, and before the start of the starvation course from 5 to 10 days, a vegetarian diet with dietary meals is adhered to, representing a vegetable diet or a vegetable diet in combination with porridges freshly prepared from whole grains of cereals. Fasting begins after emptying. Starvation course includes the main cycle having unseparated consecutive initial, main and final stages. Initial stage is 1–3 days apart food and fluid excluding water and urine. Main stage is performed for not less than 11 days with complete exclusion of food and fluid. Final stage is 1–3 days apart food and fluid excluding water and urine. Main stage of the main fasting cycle is followed by rinsing the oral cavity. Method comprises taking in patient's live E.coli and E.coli lactose-negative sticks strains and growing their cultures under artificial conditions, providing their storage during whole period of starvation, then, during the vegetarian diet after the final stage of starvation, grown cultures of typical and lactose-negative E.coli rods are taken. patient's strain. After the first emptying of the intestine, the patient is analyzed and the level of E.coli rods is checked for compliance with the norms, where normality is as follows: typical E.coli rods 10–10 CFU/g of faeces, E.coli lactose-negative <10 CFU/g of faeces, E.coli hemolytic—0. In case of deviation from norm if level of E.coli sticks is insufficient, repeated typical and/or lactose-negative E.coli rods are repeated. patient's strain, and if level of E.coli rods is excessive, the corresponding foodstuffs and/or lactose-negative E.coli rods are excluded in the next meal. If E.coli haemolytic rods are found, oral rehydration is prescribed, in which the patient should drink up to 3 liters of liquid a day.EFFECT: technical result is reduction of pain in patients, easier transfer of starvation rate.9 cl, 7 ex
PURPOSE:To obtain the titled drug for external use, promoting recovery of sunburn by applying to pigmented parts on the skin surface and returning the color to normal skin color, having high safety and capable of withstanding use for a long period, by blending tranexamic acid, salts thereof or a mixture thereof with other ingredients. CONSTITUTION:An antipigmentation drug obtained by blending tranexamic acid, salts thereof or a mixture thereof as an active ingredient with other ingredients. In use, the above-mentioned active ingredient is prepared as a blend with a pharmaceutically acceptable base and other drugs for use. An excipient, such as lactose or starch, binder, such as carboximethyl cellulose, humectant, such as talc, are used as the base to provide a form, such as lotion powder or cream. The amount of the blended active ingredient in the titled drug for external use is 0.0001-50wt.%, preferably 0.2-1wt.%. Furthermore, the tranexamic acid or salts thereof are odorless white crystalline powder, normally used as an antiplasminic agent and having 262-267 deg.C melting point.
Lenvatinib is an orally available potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1/VEGFR-1 and KDR/VEGFR. Lenvatinib has been investigated in hepatocellular carcinoma and in RAI-resistant thyroid cancer (Phase III trials) and in other malignancies, showing high rates of activity. In RAI-resistant thyroid cancer, lenvatinib showed a remarkable response rate over placebo (65% vs 2), combined with a prolonged progression free survival (18.3 vs 3.6 months). It has been approved for the treatment of locally recurrent or metastatic, progressive RAI resistance-DTC in the United States, Europe, and Japan, based on the results from SELECT trial. Moreover, lenvatinib demonstrated a meaningful clinical activity (response rate 64.8% in treatment arm vs 1.5% in placebo arm, p\<0.001;) significantly reducing the tumour burden, with a median maximum percentage change in tumour size of -42.9%. Response was mostly pronounced at the first assessment (median -24.7% at 8 weeks after randomization) but it has been observed even in the following months (-1.3% per month). Recently, the efficacy of lenvatinib was confirmed in specific patient population, such as elderly. Although the efficacy is remarkable toxic effects are considerable and not all patients have the same risk to benefit ratio from lenvatinib treatment. Results derived from controlled clinical trials are rarely replicable in the real-life because these trials are usually conducted in selected populations, in a highly controlled setting, optimized to show the effect of the drug.

In this context growing evidences are showing gender associated functions playing a role in cancer incidence, progression and response to therapy; gender disparities in toxicities and effectiveness of certain drugs used in the treatment of the most common cancer is already well known.The aim of the present study is to evaluate the safety and efficacy profile of Lenvatinib based on gender in patients with refractory iodine DTC.
Two vehicle-controlled clinical studies were conducted in patients 12 to 30 years of age with mild to moderate acne vulgaris, in which DIFFERIN® Cream was compared with its vehicle. Patients were instructed to apply their treatment medication once daily at bedtime for 12 weeks. In one study patients were provided with a soapless cleanser and were encouraged to refrain from using moisturizers. No other topical medications, other than DIFFERIN® Cream, were to be applied to the face during the studies. DIFFERIN® Cream was significantly more effective than its vehicle in the reduction of acne lesion counts. The mean percent reduction in lesion counts from baseline after treatment for 12 weeks are presented in the following table:

The trend in the Investigator’s global assessment of severity supported the efficacy of DIFFERIN® Cream when compared to the cream vehicle.
BACKGROUND: The direct anterior approach (DAA) for total hip arthroplasty (THA) is attracting attention as a minimally invasive surgery, but the learning curve to master this approach is a concern, and its effect on long-term results is unknown. The purpose of this prospective cohort study was to clarify how the learning curve affects the 5-year results of DAA THA with a traction table.
METHODS: Of 402 THA cases using DAA with a mobile traction table and fluoroscopy, 249 cases composed of the first 50 cases for each surgeon were assessed during a learning curve, and 153 cases were evaluated after more than 50 cases of experience.
RESULTS: The 5-year-implant survival rate was 99.2% both during and after the learning curve. The 2-year complication rate in the learning curve group was 8.9 versus 5.9%, which was not statistically significant. The 2-to-5-year complication rates also did not differ between the cohorts (0 versus 0.7%). Both groups demonstrated decreased complication rates when comparing 2-year complications to 2-to-5-year complications. Clinical scores significantly improved by 2 years and were maintained at 5 years in both groups. The cup safe-zone success rates were 96.4% during the learning curve and 98.7% after the learning curve. The stem safe-zone success rates were 97.2% during the learning curve and 96.1% after the learning curve. Surgical time was approximately 20 minutes shorter after the first 50 cases than during the learning curve (70.8 versus 90.6 minutes, P = .001). Intraoperative blood loss was significantly less after the learning curve than during the learning curve.
CONCLUSIONS: This study implies that the learning curve affects perioperative results such as surgical time and intraoperative blood loss, but has little effect on short-term results up to 2 years after surgery and no effect on mid-term results from 2 to 5 years after surgery.
Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
Objective: To investigate the clinicopathological and genetic features of confined placental mosaicism (CPM) and its effect on fetal intrauterine growth. Methods: Fourteen CPM cases of Haidian Maternal and Children Health Hospital were collected from May 2018 to March 2022. Clinicopathological examination on placental specimens and molecular genetic analysis were performed. Results: The age of the parturient women ranged from 27 to 34 years, with an average age of (30.0±3.54) years. The gestational weeks ranged from 35+1 to 41+2 weeks. There were 4 premature births and 10 term births, among which 6 were female and 8 were male fetuses. Nine cases (9/14) had adverse pregnancy outcomes, including 7 cases of fetal growth restriction. The weight of CPM placenta decreased, with 6 cases below the 10th percentile of weight standards and 5 cases between the 10th and 25th percentile. All 14 CPM placental specimens showed morphological changes of perfusion dysfunction to varying degrees, with mainly placental-maternal vascular malperfusion followed by placental-fetal vascular malperfusion. The mosaic chromosomes in different CPM cases varied, with 16-trisomy/monosomy mosaicism being the most common followed by 7-trisomy and 21-trisomy/monosomy mosaicism. The mosaic proportion was unequal in different parts of the same CPM placenta, with the mosaic proportion of umbilical cord, fetal membranes, fetal surface, maternal surface, and edge ranging from 1% to 70%. Conclusions: The mosaic chromosomes in different CPM cases vary, and the mosaic proportion is unequal in different parts of the same CPM placenta. The pathological morphology is mainly manifested as perfusion dysfunction, which can lead to adverse pregnancy outcomes such as fetal growth restriction and preterm birth.
Between 25 % - 50 % of women of childbearing age have uterine fibroids. Also, 25% of women with fibroids suffer from the metrorrhagia, menorrhagia, dysmenorrheal or pelvic compression so that they don't have a good quality of life. The worse case is the fertility of patients with fibroids is hindered. The current clinical treatment is medication or surgery. Medication can only suppress the symptom temporarily when the hysterectomy method of removing part or all of uterus can cure the patient completely. However, the hysterectomy is an invasive operation and the women with fibroids who plan to have a baby don't accept this kind of treatment.

Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids has been developed and was approved by the US Food and Drug Administration (FDA) in 2004. The ultrasound waves emitted by the ultrasonic probe propagate through the skin, fat, muscle, soft tissues and converge on fibroids at focus. High energy/intensity at focus causes the thermal necrosis of the fibroid tissue in several seconds. The whole process of HIFU ablation of fibroids is monitored and guided by MR thermometery. The advantage of MR-HIFU modality includes no incision, outpatient treatment and few side effects.

The objectives of this program are to verify the safety and effectiveness of the MRgHIFU system developed by the division of Medical Engineering of National Health Research Institutes (NHRI), to achieve the clinical trial at the Chang-Gung Memorial Hospitals of Linkou and to commercialize the self-developed MRgHIFU system. The mission is to conduct the first-stage clinical test for 10 women with symptomatic uterine fibroids and to make two sets of HIFU system. Meanwhile, the impact of quality of life and satisfaction with treatment of the patients diagnosed with symptomatic uterine fibroids will be analyzed.
<P>PROBLEM TO BE SOLVED: To provide a new medicinal use using MITE.  <P>SOLUTION: A mast cell death inducer or mast cell-related disease-preventing or treating agent contains a fused protein comprising PTD and MITF mutant as an active ingredient. In the fused protein comprising HisTag, PTD and MITF mutant, the MITF mutant is the mi mutant of MITF, wh mutant, HLH fragment or type A N-terminal region (1 to 305) fragment, and PTD is a peptide originated from TAT. DNA encodes the fused protein. The method for producing the fused protein uses a genetic engineering means. The fused protein is transferred into a mast cell to exhibit an action for inhibiting the activity of endogenous MITF, an action for inhibiting the existence of the mast cell from a precursor cell, an action for inducing mature cell into cell death (apoptosis), and the like.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
FIELD: medicine. SUBSTANCE: method involves stimulating anti-idiotypic response in unirradiated mice F1(BALB/c x C57BL/6)-recipients of maternal splenocytes (C57BL/6). It is achieved by immunizing recipients with antibodies against superficial antigens of BALB/c lymphocytes as transplant-host response targets. The antibodies are produced by immunizing intermediate recipient of the third haplotype with BALB/c lymphocytes, separated on immunosorbent prepared from the lymphocytes and immobilized on dialdehydecellulose for increasing immunogenicity. EFFECT: enhanced effectiveness of treatment. 3 dwg
PROBLEM TO BE SOLVED: To obtain a new physiologically active substance which originates from a microorganism in Aspergillus, a glycoprotein bearing an asparagine type saccharide chain adsorbed to Con. A, has carcinostatic action and is effective for treatment of solid cancer, ascites-type cancer, polymorphous cellular sarcoma. SOLUTION: This new physiologically active substance originates from a microorganism in Aspergillus, bears an asparagine type saccharide chain adsorbed to Con. A, has a carcinostatic action and is effective for treatment of solid cancer, ascites-type cancer, polymorphous cellular sarcoma and human dental mouth cavity tumor. This substance is obtained by culturing Aspergillus flavus SRT-K strain (FERM BP-5030), treating the cell bodies with an enzyme such as a novozyme and a surfactant, for example, sodium dodecylbenzenesulfonate, destroying the cell bodies by promptly dropping the osmotic pressure, and collecting the fraction which is adsorbed to the Con. A.
There will be one single administration of intranasal human insulin (80IU) before alcohol self-administration. After a one week washout period, there will be one single intranasal administration of placebo (saline, 0.9% solution) before alcohol self administration.
The present invention provides a polymer micelle composition capable of stably encapsulating and suitably releasing a drug, and a pharmaceutical composition using the polymer micelle composition. The polymer micelle composition comprises block copolymers each having a hydrophobic polymer chain segment  12  and a hydrophilic polymer chain segment  11.  The composition has a structure that a plurality of the block copolymers are arranged radially in a state in which the hydrophobic polymer chain segment  12  is directed inward and the hydrophilic polymer chain segment  11  is directed outward. The composition includes a block copolymer  10  having affinity with HDL  20  as the block copolymers. In the composition, detachment of the block copolymer  10  having affinity with HDL  20  is induced by HDL  20  adhesion attributed to the affinity, then a gap formed through the detachment causes promotion of release of a drug  50  to be encapsulated. The composition allows control of a release speed of the drug to be encapsulated by further including a block copolymer having affinity with a lipoprotein excluding HDL.
PURPOSE: Despite lifestyle changes and medication therapies, weight loss is difficult to maintain. Metabolic and bariatric surgery (MBS) is an effective route for significant weight reduction. However, post-operation there are limited opportunities to support weight loss maintenance. The following study aimed to pilot test a 6-week, 6-session nutrition and support program for post-MBS surgery patients.
MATERIALS AND METHODS: A 6-week post-MBS pilot nutrition and support program was developed to test feasibility and acceptability. Participants completed a baseline survey that included demographics, weight changes, success post-surgery, and self-efficacy of leading a healthy lifestyle. Weight change, percent total weight loss, self-efficacy, and program evaluation measures were assessed.
RESULTS: Participants (n = 18) were recruited from a local MBS clinic, predominately female (88.9%), non-Hispanic white (94.4%), received sleeve gastrectomy surgery (100%), and were 2-3 years post-operation (44.4%). Eight of the 18 participants attended the in-person sessions, serving as the intervention group. Both weight loss over and behavioral variables remained stable for both groups across the 6 weeks with no significant differences from pre to post program (p > 0.05). For program evaluation, intervention participants "agreed" or "strongly agreed" with 10 of 11 program satisfaction measures.
CONCLUSION: Following the program, weight loss was maintained among both intervention and control groups. Intervention feedback indicated that the program's approach to provide nutrition education and support was successful and acceptable. Future enhancement of the intervention should include a broader multidisciplinary approach, longer intervention period, and intentional recruitment of participants with a weight regain.
BACKGROUND: Although the outcomes of living donor liver transplantation (LDLT) for pediatric acute liver failure (PALF) have improved, patient survival remains lower than in patients with chronic liver disease. We investigated whether the poor outcomes of LDLT for PALF persisted in the contemporary transplant era.
METHODS: We analyzed 193 patients who underwent LDLT between December 2000 and December 2020. The outcomes of patients managed in 2000-2010 (era 1) and 2011-2020 (era 2) were compared.
RESULTS: The median age at the time of LDLT was 1.2 years both eras. An unknown etiology was the major cause in both groups. Patients in era 1 were more likely to have surgical complications, including hepatic artery and biliary complications (p = 0.001 and p = 0.013, respectively). The era had no impact on the infection rate after LDLT (cytomegalovirus, Epstein-Barr virus, and sepsis). The mortality rates of patients and grafts in era one were significantly higher (p = 0.03 and p = 0.047, respectively). The 1- and 5-year survival rates were 76.4% and 70.9%, respectively, in era 1, while they were 88.3% and 81.9% in era 2 (p = 0.042). Rejection was the most common cause of graft loss in both groups. In the multivariate analysis, sepsis during the 30 days after LDLT was independently associated with graft loss (p = 0.002).
CONCLUSIONS: The survival of patients with PALF has improved in the contemporary transplant era. The early detection and proper management of rejection in patients, while being cautious of sepsis, should be recommended to improve outcomes further.
In-person group will be followed with standard-of-care clinic visits scheduled with an pediatric orthopaedic Surgeon at Carilion Clinic Institute for Orthopaedics and Neurosciences. Participants will complete a pediatric PROMIS assessment at baseline and 6 weeks for . Patients/guardians will complete a satisfaction survey.
Naproxen tablets, USP are nonsteroidal anti-inflammatory drugs and available as follows: Naproxen tablets, USP are available as light yellow round shaped tablets containing 250 mg naproxen, light yellow capsule shaped tablets containing 375 mg naproxen, and light yellow oblong shaped tablets containing 500 mg naproxen for oral administration.

Naproxen is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical name for naproxen is (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid. Naproxen has a molecular weight of 230.26 and a molecular formula of C 14H 14O 3. It has the following structural formula: 

Naproxen is white or almost white crystalline powder. It is insoluble in water, soluble in chloroform, dehydrated ethanol and methanol. Sparingly soluble in ether. The octanol/water partition coefficient of Naproxen at pH < 2.18 is 3.18.

Each naproxen tablet, USP contains the following inactive ingredients: croscarmellose sodium, yellow iron oxide, povidone and magnesium stearate